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Abstract
The study objective was to test the hypothesis that having histocompatible children increases the risk of rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE), possibly by contributing to the persistence of fetal cells acquired during
pregnancy. We conducted a case control study using data from the UC San Francisco Mother Child Immunogenetic Study and
studies at the Inova Translational Medicine Institute. We imputed human leukocyte antigen (HLA) alleles and minor
histocompatibility antigens (mHags). We created a variable of exposure to histocompatible children. We estimated an average
sequence similarity matching (SSM) score for each mother based on discordant mother−child alleles as a measure of
histocompatibility. We used logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals. A total of
138 RA, 117 SLE, and 913 control mothers were analyzed. Increased risk of RA was associated with having any child
compatible at HLA-B (OR 1.9; 1.2–3.1), DPB1 (OR 1.8; 1.2–2.6) or DQB1 (OR 1.8; 1.2–2.7). Compatibility at mHag ZAPHIR
was associated with reduced risk of SLE among mothers carrying the HLA-restriction allele B*07:02 (n= 262; OR 0.4; 0.2–
0.8). Our findings support the hypothesis that mother−child histocompatibility is associated with risk of RA and SLE.
Introduction
Rheumatoid arthritis (RA) and systemic lupus erythemato-
sus (SLE) are two prototypic autoimmune conditions.
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Despite differing clinical manifestations, a common feature
is the production of B- and T-cell responses directed against
self-antigens. Both diseases have strong associations with
human leukocyte antigen (HLA) alleles [1] and pre-
dominately affect women [2, 3]. In RA, the female to male
ratio is 3:1 and 9:1 in SLE [3]. The sex disparity has
prompted investigation into various female-specific expo-
sures, including those related to pregnancy [2], as potential
etiologic factors.
The effect of pregnancy on RA and SLE activity is well
documented and supports the hypothesis that immunologic
changes during pregnancy are implicated in RA and SLE
disease processes. The improvement of RA symptoms with
pregnancy has been noted for decades [4, 5]. In SLE,
relative to nonpregnant patients, pregnant patients have
higher disease activity scores [6] and experience more flares
[7]. Risk of RA increases during the first 2 years after birth
[8–10]. In contrast to RA, a recent birth is associated with a
reduction in risk of developing SLE lasting up to 10 years
[11]. HLA disparity has been associated with improvement
of RA symptoms during the course of pregnancy [12–14]
and with delayed onset of RA post-pregnancy [13]. Per-
sistent fetal microchimerism is more common in RA and
SLE patients compared to controls [15]. One hypothesis is
that the persistence of fetal cells in the mother’s body may
be analogous to a graft and its immunological effect may be
mediated by HLA relationships between mother and fetus
[16].
The effects of HLA mismatch have been extensively
investigated in the context of transplantation. HLA mis-
match is associated with increased risk of graft-versus-host
disease (GVHD) [17] as is mismatching on minor histo-
compatibility antigens (mHags) among HLA-matched
donor−recipients [18]. mHags are polymorphic peptides
encoded by genes outside of the HLA region that are pre-
sented in an HLA-restricted manner, meaning that the
peptide binds to specific HLA molecules [19]. The simila-
rities between GVHD and the clinical manifestations of
certain autoimmune conditions have led to the hypothesis
that mother−child HLA mismatch may contribute to female
autoimmune disease processes [20, 21]. However, these
studies have been limited to the investigation of a small
number of HLA loci. The objective of this study was to
investigate the association between RA and SLE and
mother−child histocompatibility at seven classical HLA
loci and six HLA-restricted mHags in a cohort of mother
−child pairs.
Results
RA and SLE cases were older at the time of interview or
electronic medical record (EMR) extraction compared to
controls (Table 1). On average, RA cases were diagnosed at
age 39 and SLE cases at age 42. Cases had a greater number
of live births compared to the average number among
controls.
Mother−child histocompatibility
Over the seven individual HLA loci tested in RA and SLE
separately, HLA-B, DPB1 and DQB1 were associated with
increased risk of RA when mothers had one or more chil-
dren prior to diagnosis who were histocompatible from the
mother’s perspective (Table 2). The association between
HLA-B and RA was odds ratio (OR) 1.9; 95% confidence
interval (CI), 1.2–3.1, between DPB1 and RA OR 1.8; 95%
CI, 1.2–2.6 and OR 1.8; 95% CI, 1.2–2.7 between DQB1
and RA. Among SLE cases, there was no evidence of an
association between having any histocompatible children at
any of the classical HLA loci tested and risk of disease
(Table 3). A minority of cases and controls had children
who were histocompatible at all seven loci (3.6% of RA
cases, 1.7% of SLE, and 0.8% of controls). We found a
significant difference between cases and controls and the
proportion of missing histocompatibility status at DQB1
(controls 6%, RA 16%, SLE 25% missing) and between
SLE status and HLA-A (controls 3% and SLE 6%). No other
differences were found at the other loci tested.
Results using the SSM score to categorize mother−child
compatibility at each locus are found in Tables 4 and 5. The
SSM score range varied across HLA loci. Supplementary
Table 1 Characteristics of
mothers by rheumatoid arthritis
(RA), systemic lupus
erythematosus (SLE) and
control status
Characteristics RA SLE Controls
Na 138 117 913
Age at interview, mean ± SD 56.0 ± 9.2 56.3 ± 10.7 36.5 ± 9.2
Number of live births, mean ± SD 2.2 ± 1.0 2.4 ± 1.2 1.9 ± 0.9
Number of live births prior to diagnosis, mean ± SD 2.0 ± 1.0 2.2 ± 1.2 —
Years between last birth before diagnosis and diagnosis, mean ± SDb 13.5 ± 11.0 16.1 ± 10.4 —
Age at diagnosis, mean ± SD 39.4 ± 11.6 42.7 ± 10.6 —
aParticipants included in HLA-compatibility analyses
bAge at last birth before diagnosis available for 120 RA cases
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Figures 1 to 7 present the SSM score distribution at each
locus by disease status. DQA1 had the smallest range in
score and HLA-A and B had the greatest. Results for cases
and controls were very similar (Supplementary Table 4). All
estimates from the multivariable models comparing the top
quartile of similarity to the least and their association with
RA and SLE contained the null (Tables 4 and 5). The SSM
score was correlated with our allele-based definition of
histocompatibility where average scores were significantly
lower in the histocompatible group, as expected (data not
shown).
Minor histocompatibility antigen compatibility
Table 6 shows results for association tests between mHag
compatibility versus incompatibility and SLE among
mothers. The number of mothers who carried the HLA
restriction allele for each mHag determined the sample size
for each model (Table 6). We found evidence of reduced
SLE risk associated with having one or more children who
were compatible for ZAPHIR, restricted for HLA-B*07:02,
regardless of mother−child histocompatibility status; OR
0.4; 95% CI, 0.2–0.8. Taking HLA compatibility into
account (Table 7), SLE cases were less likely to have HLA-
compatible/mHag compatible children (yes/no) at ZAPHIR
compared to controls (0% vs. 9% respectively, Fisher’s
exact p value= 0.05). However, HLA-compatibility com-
bined with mHag compatibility at LB-WNK1 was more
likely among cases than control mothers (23% vs. 13%
respectively, Fisher’s exact p value= 0.02). We did not
observe associations between compatibility and SLE at
other mHags investigated.
Discussion
Our study addressed the hypothesis that mother−child
histocompatibility increases risk of RA and SLE possibly
Table 2 Association between one or more children histocompatible
from the mother’s perspective among rheumatoid arthritis (RA) cases
compared to controls (analyses are for each HLA locus and are
adjusted for number of live births)
Any
histocompatible
children
RA
n (%)
Controls
n (%)
OR (95% CI) Bonferroni
corrected p
valuea
HLA Class I
A
None 104 (75) 683 (75) Reference
1 or more 34 (25) 230 (25) 1.0 (0.6–1.5) 1.00
B
None 111 (80) 814 (89) Reference
1 or more 27 (20) 99 (11) 1.9 (1.2–3.1) 0.04
C
None 105 (76) 752 (82) Reference
1 or more 33 (24) 161 (18) 1.4 (0.9–2.2) 0.77
HLA Class II
DPB1
None 63 (46) 555 (61) Reference
1 or more 75 (54) 358 (39) 1.8 (1.2–2.6) 0.01
DQA1
None 74 (54) 597 (65) Reference
1 or more 64 (46) 316 (35) 1.6 (1.1–2.3) 0.10
DQB1
None 93 (67) 725 (79) Reference
1 or more 45 (33) 188 (21) 1.8 (1.2–2.7) 0.03
DRB1
None 103 (75) 765 (84) Reference
1 or more 35 (25) 148 (16) 1.6 (1.0–2.4) 0.28
OR odds ratio, 95% CI, confidence interval
aBonferroni corrected p values for seven tests
Table 3 Association between one or more children histocompatible
from the mother’s perspective among systemic lupus erythematosus
(SLE) cases compared to controls (analyses are for each HLA locus
and are adjusted for number of live births)
Any
histocompatible
children
SLE
n (%)
Controls
n (%)
OR (95% CI) Bonferroni
corrected p
valuea
HLA Class I
A
None 78 (67) 683 (75) Reference
1 or more 39 (33) 230 (25) 1.5 (1.0–2.3) 0.35
B
None 101 (86) 814 (89) Reference
1 or more 16 (14) 99 (11) 1.2 (0.7–2.2) 1.00
C
None 92 (79) 752 (82) Reference
1 or more 25 (21) 161 (18) 1.2 (0.7–1.9) 1.00
HLA Class II
DPB1
None 64 (55) 555 (61) Reference
1 or more 53 (45) 358 (39) 1.3 (0.9–1.9) 1.00
DQA1
None 69 (59) 597 (65) Reference
1 or more 48 (41) 316 (35) 1.2 (0.8–1.9) 1.00
DQB1
None 85 (73) 725 (79) Reference
1 or more 32 (27) 188 (21) 1.4 (0.9–2.1) 1.00
DRB1
None 103 (75) 765 (84) Reference
1 or more 35 (25) 148 (16) 1.3 (0.8–2.2) 1.00
OR odds ratio, 95% CI confidence interval
aBonferroni corrected p values for seven tests
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by facilitating the persistence of fetal cells. We found that
RA cases were more likely to have a child histocompatible
at HLA-B, DPB1 and DQB1 compared to controls. Our
findings are consistent with previous studies that found an
association between decreased disease activity during
pregnancy and DQA1 and DQB1 incompatibility [12, 13].
One hypothesis is that incompatibility results in competition
between fetal and maternal self-antigens, where one dis-
places the other leading to an improvement of symptoms or
delayed onset. Compatibility may increase risk of disease
by contributing to the process of epitope spreading prior to
disease onset [22], if the quantity of risk-associated antigens
increases with pregnancy. Compatibility may diminish T-
reg activation that helps to shift the balance of Th1/Th2
cytokines. Paternal antigens induce T-regs independent of
pregnancy hormones in murine models of pregnancy [23].
We found no association between histocompatibility and
SLE. The lack of consistency between the two diseases does
not support the hypothesis that histocompatibility functions
as a common mechanism in autoimmunity, such as by
facilitating the persistence of fetal cells. Our findings do not
Table 4 Mean sequence similarity matching (SSM) score and risk of
rheumatoid arthritis (RA) among mothers
Histocompatibility per
SSM score (Quartile)
RA
n (%)
Controls
n (%)
OR (95%
CI)a
p for
linear
trend
HLA Class I
A
Least (4th) 30 (22) 222 (24) Reference
Most (1st) 35 (25) 229 (25) 1.2 (0.7–
2.0)
0.35
B
Least (4th) 37 (27) 231 (25) Reference
Most (1st) 34 (25) 231 (25) 1.0 (0.6–
1.6)
0.99
C
Least (4th) 35 (25) 209 (23) Reference
Most (1st) 32 (23) 227 (25) 0.8 (0.5–
1.4)
0.52
HLA Class II
DPB1
Least (4th) 24 (17) 220 (24) Reference
Most (1st) 42 (30) 244 (27) 1.5 (0.9–
2.6)
0.26
DQA1
Least (4th) 22 (16) 218 (24) Reference
Most (1st) 24 (17) 221 (24) 1.1 (0.6–
2.0)
0.65
DQB1
Least (4th) 28 (20) 295 (32) Reference
Most (1st) 33 (24) 221 (24) 1.6 (0.9–
2.8)
0.04
DRB1
Least (4th) 23 (17) 210 (23) Reference
Most (1st) 34 (25) 244 (27) 1.3 (0.7–
2.3)
0.65
OR odds ratio, 95% CI confidence interval
aAdjusted for number of live births. The SSM score estimates degree
of similarity between two alleles. A lower score indicates increased
similarity relative to a higher score; therefore, the fourth quartile of
scores is intended to represent the least histocompatible group and the
first quartile the most
Table 5 Mother−child similarity score—Mean sequence similarity
matching (SSM) score and risk of systemic lupus erythematosus (SLE)
among mothers
Histocompatibility per
SSM score (Quartile)
SLE
n (%)
Controls
n (%)
OR (95%
CI)a
p for
linear
trend
HLA Class I
A
Least (4th) 26 (22) 222 (24) Reference
Most (1st) 31 (27) 229 (25) 1.2 (0.7–
2.2)
0.46
B
Least (4th) 23 (20) 231 (25) Reference
Most (1st) 37 (32) 231 (25) 1.5 (0.9–
2.7)
0.23
C
Least (4th) 30 (26) 209 (23) Reference
Most (1st) 26 (22) 227 (25) 0.8 (0.4–
1.4)
0.19
HLA Class II
DPB1
Least (4th) 26 (22) 220 (24) Reference
Most (1st) 19 (16) 244 (27) 0.7 (0.3–
1.2)
0.04
DQA1
Least (4th) 26 (22) 218 (24) Reference
Most (1st) 19 (16) 221 (24) 0.7 (0.4–
1.4)
0.25
DQB1
Least (4th) 29 (25) 295 (32) Reference
Most (1st) 18 (15) 221 (24) 0.8 (0.4–
1.5)
0.89
DRB1
Least (4th) 14 (12) 210 (23) Reference
Most (1st) 28 (24) 244 (27) 1.7 (0.9–
3.3)
0.42
OR odds ratio, 95% CI confidence interval
aAdjusted for number of live births. The SSM score estimates degree
of similarity between two alleles. A lower score indicates increased
similarity relative to a higher score; therefore, the fourth quartile of
scores is intended to represent the least histocompatible group and the
first quartile the most
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rule out that histocompatibility contributes to autoimmunity
through other mechanisms and highlight the importance of
considering the contrasting pattern of the effect of preg-
nancy on RA and SLE [24]. The findings that incompat-
ibility is associated with remission and delayed onset are
consistent with a mechanism of action based on increased
production of T-regs during pregnancy that shifts the Th1/
Th2 balance in RA. Lupus flares during pregnancy are more
likely in women with active disease at the time of preg-
nancy [25]. In lupus pregnancy, complement activation has
been implicated in flares during pregnancy [26], high-
lighting the distinct immunological pathways that lead to
each disease.
HLA Class II incompatibility has been reported to be
associated with remission or improvement of RA symptoms
during pregnancy and possibly with risk of developing RA
in the post-partum period [12, 13]. One study found
increased risk of RA in the first year after birth was asso-
ciated with incompatibility at DQA1 (OR 3.86; 95% CI,
1.03–14.52) and DQB1 (OR 4.23, 95% CI, 1.12–15.9) [13].
However, the study was based on a small sample of 16
women who developed RA during this period. Compat-
ibility at HLA Class II has been associated with increased
risk of scleroderma [27]. Among controls, the frequency of
compatibility in our study at DRB1 (17%) and DQA1 (35%)
was similar to the one reported in the scleroderma study (16
and 34% respectively) [27]. Estimates for cases differ
according to disease, possibly due to relative differences in
pathophysiology. Our findings are in agreement with a
previous study that failed to find evidence of an association
between mother−child histocompatibility at DRB1 and SLE
[28].
Compatibility at the minor histocompatibility antigen
ZAPHIR was associated with decreased risk of SLE among
mothers who carried the presenting HLA allele B*07:02
(OR 0.4; 95% CI, 0.2–0.8). Furthermore, we found a similar
association when analyses were restricted to the group of
mothers and children who were both histocompatible at
HLA-B and ZAPHIR (p= 0.05). ZAPHIR was identified in
the context of graft-versus-tumor effect in patients with
renal cell carcinoma [29]. In the case of one patient who
experienced a partial regression of lung metastasis after
stem cell transplantation found that the presence of
ZAPHIR-specific CD8+ T cells resulted in a graft-versus-
Table 6 Mother−child compatibility at minor histocompatibility
antigens (mHag) and risk of systemic lupus erythematosus (SLE)
among mothers with the corresponding HLA restriction
Any mHag-
matched
children
HLA restriction SLE
n (%)
Controls
n (%)
OR (95%
CI)a
p
SLC19A1 DRB1*15:01
None 24 (52) 111 (53) Reference
1 or more 22 (48) 98 (47) 0.9 (0.5–
1.7)
0.76
LB-WNK1 A*02:01
None 45 (47) 252 (57) Reference
1 or more 50 (53) 188 (43) 1.5 (0.9–
2.3)
0.11
HA-3 A*01:01
None 32 (48) 152 (52) Reference
1 or more 34 (52) 140 (48) 1.2 (0.7–
2.1)
0.50
ZAPHIR B*07:02
None 29 (74) 117 (52) Reference
1 or more 10 (26) 106 (48) 0.4 (0.2–
0.8)
0.01
HEATR1 B*08:01
None 31 (54) 127 (64) Reference
1 or more 26 (46) 73 (37) 1.5 (0.8–
2.7)
0.22
C19orf48 A*02:01
None 44 (46) 245 (56) Reference
1 or more 51 (54) 195 (44) 1.4 (0.9–
2.3)
0.13
OR odds ratio, 95% CI confidence interval
aAdjusted for number of live births
Table 7 Fisher’s Exact test between having any children who are
mHag and HLA compatible and risk of systemic lupus erythematosus
(SLE) among mothers (histocompatible from the mother’s perspective
at the restriction HLA locus and at the minor histocompatibility
antigen)
Any HLA-matched/
mHag-matched
children
HLA restriction SLE
n (%)
Controls
n (%)
pa
SLC19A1 DRB1*15:01
None 44 (96) 189 (90)
1 or more 2 (4) 20 (10) 0.39
LB-WNK1 A*02:01
None 73 (77) 384 (87)
1 or more 22 (23) 56 (13) 0.02
HA-3 A*01:01
None 57 (86) 251 (86)
1 or more 9 (14) 41 (14) 1.0
ZAPHIR B*07:02
None 39 (100) 202 (91)
1 or more 0 (0) 21 (9) 0.05
HEATR1 B*08:01
None 51 (89) 189 (95)
1 or more 6 (11) 11 (5) 0.22
C19orf48 A*02:01
None 75 (79) 366 (83)
1 or more 20 (21) 74 (17) 0.37
aFisher’s exact test p value
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tumor effect and prevented against GVHD. In SLE, these
findings merit further investigation due to renal involvement
in more severe disease.
SLE cases were more likely to be compatible at both LB-
WNK1 and at its HLA-A restriction site compared to con-
trols (p= 0.02). LB-WNK1 is encoded by WNK1 [19].
WNKs are kinases associated with hypertension and
involved in the regulation of sodium and potassium ions
and water status in the nephron [30]. Elevated risk of pre-
eclampsia among SLE pregnancies compared to the general
population, including prior to disease onset [31] supports a
potential biological relevance for the observed association.
WNK1 deficiency in mice increases conjugation between
T cells and antigen-presenting cells and T cells home less
efficiently to lymph nodes and spleen [32]. WNK1 has been
found to be involved in the establishment of pregnancy and
regulation of inflammatory cytokines [33]. Functional stu-
dies in SLE and pre-SLE pregnancies are needed to
understand the significance of compatibility in the disease
process.
Minor histocompatibility antigen disparity is immuno-
genic as evident from their involvement in GVHD among
HLA-matched transplant recipients and in the potentially
curative graft-versus-leukemia effect (GVL) [34]. The use
of mismatched mHags as a way to trigger GVL is evidence
that mHags can be manipulated for therapeutic applications
[35]. As more mHags are discovered, their relevance and
function is likely to depend on the context of the interaction.
This study is among the first investigations of mother
−child mHag compatibility and risk of SLE. CD8+ T cells
specific for minor histocompatibility antigens of fetal origin
have been found in mothers up to 22 years after delivery
[36] as have mHag-specific regulatory T cells (T-regs) [37].
Exposure to fetal mHags is likely to come from micro-
chimerism or from particles that are shed from the placenta
and enter the maternal circulation [38]. Minor histo-
compatibility antigens are expressed in placental material
[39]. Placental vesicles of various sizes carry fetal nucleic
acids, proteins and lipids and are hypothesized to have
immunomodulatory effects [40, 41]. It is possible that
antigens from fetal sources mediate the effect of pregnancy
on RA and SLE. The shedding of placental material could
overload the dysfunctional clearance mechanism in SLE
patients, leading to exacerbation of symptoms [42]. Func-
tional studies of maternal immune cell responses to fetal
minor histocompatibility antigens are needed to understand
their biological effect in the context of autoimmunity.
Strengths and limitations
We describe a comprehensive report on mother−child his-
tocompatibility and risk of RA and SLE. We conducted a
case−control study in a well-characterized mother−child
study of autoimmunity. The MCIS is a unique resource with
genotype data for case and control families, detailed ques-
tionnaire and medical record abstracted clinical data. Our
exposure definition of histocompatibility at both classical
HLA loci and minor histocompatibility antigens was based
on biology.
Some study limitations must be acknowledged. The use
of SNP2HLA to impute alleles at two-field resolution for
HLA-A, B, C, DPB1, DQA1, DQB1 and DRB1 resulted in
different degrees of missing data by locus. This is possibly
due to the use of data derived from different genotyping
platforms. For the most part, missingness was not associated
with case control status with the exception of DQB1. Both
RA and SLE cases were more likely to have a missing value
for histocompatibility at DQB1 compared to controls. It is
possible that the SNPs available for imputation of DQB1
alleles for RA and SLE cases were not sufficient. For this
reason, the association between histocompatibility at DQB1
and RA and SLE requires further investigation. There were
also more missing data for HLA-A histocompatibility and
SLE but the difference between cases and controls was
small (3%) and it is unlikely this difference would sub-
stantially impact results.
Inclusion of controls from pregnancy cohorts at ITMI
resulted in a significant difference in the age at interview or
EMR data extraction. It is possible that the younger age of
controls could bias our results by including future cases.
However, RA and SLE are both relatively rare in the gen-
eral population and we expect similar rates apply to this
cohort. Moreover, inclusion of future cases is likely to bias
our results towards the null. Differences in data collection
(self-administered questionnaire vs. EMR) could result in
information bias. For our study, the only variable included
in analyses was the number of live births. Studies have
shown a high level of concordance in the number of live
births reported by self-report and medical records (kappa=
1.0) [43, 44], therefore minimizing concern that the method
of collection contributed to the results. The lower number of
live births among controls compared to cases could reduce
the probability of exposure. However, all models are
adjusted for the number of live births.
In conclusion, we found new evidence for mother−child
HLA-mediated effects in RA and SLE. A comprehensive
evaluation of immunogenic peptides, such as minor histo-
compatibility antigens, is needed, as they may help explain
pregnancy-related effects and may be promising therapeutic
targets.
Patients and methods
We conducted a case−control study of 3746 individuals
including 1614 non-Hispanic white mothers and their 2132
32 G. I. Cruz et al.
children. All mothers had at least one child who provided
blood or saliva for DNA extraction. Data for mothers and
children were obtained from the University of California
San Francisco (UCSF) Mother−Child Immunogenetic
Study (MCIS) and research studies conducted at the Inova
Translational Medicine Institute (ITMI), Inova Health
System, Falls Church, Virginia. The MCIS enrolled RA and
SLE case mothers who were identified from genetic studies
of autoimmunity at UCSF. Only mothers with at least one
child born prior to diagnosis were included in the study.
Cases were ascertained by the most current American
College of Rheumatology (ACR) criteria available at the
time of enrollment. RA cases met the 1987 revised ACR
criteria [45] and SLE cases met the 1997 revised ACR
criteria [46, 47]. Control mothers with no prior history of
RA or SLE and their children were identified from various
sources. MCIS control mothers were recruited from blood
donors who had participated in the Leukocyte Antibody
Prevalence Study (LAPS) [48] at the Blood Centers of the
Pacific and the Institute for Transfusion Medicine in Pitts-
burgh, PA. Data for mother−child control pairs were also
obtained from the ITMI’s Molecular Study of Preterm Birth
and the First 1000 Days of Life studies. Family trios
composed of a neonate and both parents were recruited at
the Inova Women’s Hospital, Inova Fairfax Medical Center,
Falls Church, Virginia [49]. We included mother−child
pairs from ITMI cohorts if the mother was of European
ancestry and had no prior history of RA or SLE. All par-
ticipants provided written informed consent. The study
protocol is in accordance with the Declaration of Helsinki
and was approved by the UCSF and UC Berkeley Institu-
tional Review Boards (IRB). The Western IRB and the
Inova Health System IRB approved ITMI studies.
Clinical and questionnaire data
For cases, we obtained the date of diagnosis and clinical
characteristics from medical records. The MCIS collected
data from case and control mothers on reproductive history
and potential confounders through a self-administered
questionnaire. For ITMI control mothers, reproductive his-
tory, mother’s and child’s date of birth and mother’s history
of RA and SLE were obtained from electronic medical
records (EMR).
Genotyping
Cases were genotyped for a panel of 2360 SNPs in the
MHC region using the combined MHC Exon-Centric and
Mapping panels from Illumina. Full genome profiling of
MCIS controls and children was conducted using the Illu-
mina 660K SNP array or the Illumina ImmunoChip. QA/
QC criteria were applied to all genotype data resulting in the
exclusion of SNPs that were genotyped in <80% of samples
and/or had a minor allele frequency (MAF) < 1%. All
genotyping of MCIS participants was performed at UC
Berkeley. Whole-genome sequencing (WGS) data were
available for ITMI control mother−child duos. ITMI WGS
and QA/QC methods have been previously described [49].
For the Molecular Study of Preterm Birth samples WGS,
assembly and variant calling were performed by Complete
Genomics (CG) (Mountain View, CA) using Complete
Genomics’ Assembly Pipeline versions 2.0.0–2.03. The
1000 Days of Life Study samples were sequenced by Illu-
mina (San Diego, CA) with the Illumina Whole Genome
Sequencing Service Informatics Pipeline version 2.01–02.
In addition, we excluded SNPs that were genotyped in
<90% of samples and/or had an MAF < 1%. We verified
familial relationships for all mother−child duos.
HLA allele imputation
We used SNP2HLA [50] to impute HLA alleles using post-
QA/QC genotype and WGS data. After imputation, we
excluded variants with a low measure of imputation accu-
racy (r2 < 0.3). As an additional QC measure of imputation
quality, we compared imputation results at the allelic level
to typed two-field DRB1 data available for a subset of MCIS
participants (n= 2136) using the method described by
Raychaudhuri et al. [51]. The imputation procedure cor-
rectly called 93.1% of alleles. Using a chi-square test and a
significance threshold of α= 0.05, we compared allele
accuracy by platform. We did not find statistically sig-
nificant differences by platform for the DRB1 alleles
investigated (p= 0.19). The process of imputation and QA/
QC steps resulted in different sample sizes available at each
of the seven classical HLA loci (HLA-A, B, C, DPB1,
DQA1, DQB1, and DRB1) at two-field resolution. We took
a complete case approach in order to facilitate the inter-
pretation of results.
Minor histocompatibility antigens
We identified single nucleotide polymorphisms (SNPs)
correlated with minor histocompatibility antigens (mHags)
from a previously published report [52]. We obtained SNP
data for MCIS SLE cases available from other genetic
studies of autoimmunity at UCSF. ImmunoChip genotype
data were available for SLE cases and their children for
mHags SLC19A1 (rs1051266), LB-WNK1 (rs12828016),
and ZAPHIR (rs2074071). In order to investigate as many
mHags as possible, we imputed mHag SNPs using
IMPUTE2 and the 1000 genomes (Phase 3) reference panel
[53]. We excluded imputed SNPs with an info score < 0.3.
After QA/QC, we had three additional SNPs for mothers
and at least one child born prior to diagnosis: HA-3
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(rs2061821), HEATR1 (rs2275687), C19orf48
(rs3745526). For an additional QA/QC measure of impu-
tation accuracy, we compared the results of our imputed
rs2061821 with genotyped data from Illumina’s 550K
platform available for a subset of SLE cases and found
100% concordance. For ITMI controls, WGS data were
available for all six SNPs. RA mothers were not included in
this analysis due to the lack of datasets available to extract
or impute the SNPs correlated with mHags.
Classification of mother−child histocompatibility
profiles
All children were classified into one of two histocompat-
ibility categories at each classical HLA locus (HLA-A, B, C,
DPB1, DQA1, DQB1, and DRB1) and SNPs for mHags
SLC19A1, LB-WNK1, ZAPHIR, HA-3, HEATR1 and
C19orf48. For case mothers, only children born before
diagnosis were included. A child was classified as histo-
compatible from the mother’s perspective if his or her
paternally inherited allele was indistinguishable from either
of the mother’s alleles. Based on this classification, a binary
variable for having any histocompatible children was gen-
erated for each mother at each HLA locus and mHag SNP.
Histocompatibility defined by sequence similarity
matching (SSM) score
In hematopoietic stem cell transplantation an exact match
may be difficult to find. The risk of GVHD increases with
the number of mismatched alleles [54]. In the case of a
mismatch, it may be possible to reduce the risk of GVHD
by estimating the allogeneic potential of the mismatch by
selecting the least structurally different allele [55]. His-
toCheck is a bioinformatics web tool that estimates an SSM
based on amino acid sequence similarity [55]. This quan-
titative approach can be informative in estimating degree of
similarity between the noninherited maternal allele and the
paternal allele carried by the child. We estimated an SSM
score for mother−child pairs who were not HLA-identical
at each locus. Where mother and child did not differ at
either allele, we assigned a score of zero. For each mother,
we created an average SSM score at individual HLA loci.
We categorized average SSM score into four groups
according to values in the control group. Smaller values
indicate increased similarity between mothers and children
and are intended to represent greater degree of
histocompatibility.
Statistical analysis
Analyses for questions pertaining to mother−child histo-
compatibility at classical HLA loci were conducted in a
sample of 138 RA, 117 SLE, and 913 control mothers and
their respective children. We included mothers who had
complete histocompatibility data at seven HLA loci (HLA-
A, B, C, DPB1, DQA1, DQB1, DRB1). A total of 206 SLE
cases and 965 controls and 1387 children were available for
mHag-related analyses. Only cases with at least one child
with data born prior to diagnosis were included. We used
logistic regression models to estimate ORs and 95% CIs for
the association between mother’s RA and SLE status and
any histocompatibility at each HLA locus or mHag SNP
and quartiles of average SSM score. We analyzed mHag
compatibility in an HLA-restricted manner, meaning that
only mothers who carried the HLA allele associated with
the mHag were included. In addition, we tested whether
case mothers were more likely to have any HLA-compa-
tible/mHag compatible children compared to controls using
Fisher’s exact test.
We used directed acyclic graphs to identify potential
confounders and proceeded to include number of live births
in our analyses. To correct for multiple testing, we applied a
Bonferroni correction to classical HLA analyses to account
for tests at seven loci [56]. To investigate the probability of
introducing selection bias, we compared the proportion of
missing data at each of the seven HLA loci by disease status
using a chi-square test and considered a p value of
<0.05 significant. We tested for the presence of a linear
trend in our analyses of SSM score quartiles at each locus
and autoimmune disease. Statistical analyses were con-
ducted using Stata 13 (StataCorp, College Station, Texas)
and R [57].
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